Diet Pill Online > Diet Pills > Zimulti - second name for rimonabant

A second name trademarked by Sanofi-Aventis, in addition to Acomplia, for rimonabant is Zimulti. You might see the drug adverted by either name, such as SR141716, Bethin, Monaslim, Remonabent, Riobant, Slimona and Rimoslim.

At this time it seems like Sanofi is likely to practice the name Zimulti in America and Acomplia in Europe. As of June, 2006, when rimonbant was approved for sale in Europe, "Acomplia" was indeed the name chosen for European sale and Zimulti for US sale.

A customary dosage of Zimulti are counted similar to Acomplia dosage which is 20mg. They are to be swallowed in one draught with a full glass of water. Zimulti diet pill used up in conjunction with a low-calorie diet and regular exercises.

In a reports awarded at the annual meeting of the European Atherosclerosis Society in Istanbul, the researchers said computed tomography scans displayed that rimonabant discourse for a year resulted in significantly greater reducings in visceral fat than a placebo and also helped reduce the fat liver index. The results issued forth the ADAGIO-LIPIDS clinical test, a study conducted in 799 patients with abdominal muscle obesity and with the high triglyceride - low HDL-cholesterol dyslipidemia. Dyslipidemia is a condition that contributes to the development of atherosclerosis (commonly called hardening of the arteries).

In March of 2008, Zimulti gained a great deal of attention when two research studies demonstrated that rimonabant helped keep weight off for two years, lower bad cholesterol, increase good cholesterol, and it could possibly be used to fight drug and alcohol abuse.

Zimulti has not yet been made saleable in the US market as it awaits the FDA (Food and Drug Administration) approval.